Evidence map›Paper›PMID 31817742›Full record

ArticleBiomolecules2019

Participation of the miR-22-HDAC4-DLCO Axis in Patients with COPD by Tobacco and Biomass.

Yadira Velasco-Torres, Víctor Ruiz, Martha Montaño, Rogelio Pérez-Padilla, Ramcés Falfán-Valencia, Julia Pérez-Ramos, Oliver Pérez-Bautista, Carlos Ramos

Open access · goldAbstract read
In one paragraph

Article in Biomolecules, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Review
  3. Endoplasmic reticulum stress: a vital process and potential therapeutic target in chronic obstructive pulmonary disease.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yadira Velasco-TorresBiological and Health Sciences, Universidad Autónoma Metropolitana-Xochimilco (UAM-X), Mexico City 04960, Mexico.
Víctor RuizMolecular Biology Laboratory, Department of Research in Pulmonary Fibrosis, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas (INER), Mexico City 14080, Mexico.
Martha MontañoCellular Biology Laboratory, Department of Research in Pulmonary Fibrosis, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas (INER), Mexico City 14080, Mexico.ORCID 0000-0001-7296-3365
Rogelio Pérez-PadillaDepartment of Research in Smoking and COPD, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas (INER), Mexico City 14080, Mexico.
Ramcés Falfán-ValenciaHLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas (INER), Mexico City 14080, Mexico.ORCID 0000-0001-6877-8124
Julia Pérez-RamosDivision of Biological and Health Sciences, Universidad Autónoma Metropolitana-Xochimilco (UAM-X), Mexico City 04960, Mexico.
Oliver Pérez-BautistaDepartment of Research in Smoking and COPD, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas (INER), Mexico City 14080, Mexico.
Carlos RamosCellular Biology Laboratory, Department of Research in Pulmonary Fibrosis, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas (INER), Mexico City 14080, Mexico.ORCID 0000-0001-7378-6575
Instituto Nacional de Enfermedades Respiratorias · MXUniversidad Autónoma Metropolitana · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation and systemic inflammation. The main causes of COPD include interaction between genetic and environmental factors associated with tobacco smoking (COPD-TS) and/or exposure to biomass smoke (COPD-BS). Several microRNAs (miRNAs) control posttranscriptional regulation of COPD-TS associated gene expression. The miR-22-HDAC4-IL-17 axis was recently characterized. It is still unknown, however, whether this axis, participates in COPD-BS. To investigate, 50 patients diagnosed with severe-to-very severe COPD GOLD (Global Initiative for Chronic Obstructive Lung Disease) stages III/IV, were recruited, 25 women had COPD-BS (never smokers, exposed heavily to BS) and 25 had COPD-TS. Serum levels of miRNA-22-3p were measured by RT (Reverse Transcription)-qPCR, while the concentration of HDAC4 (Histone deacetylase 4) was detected by ELISA. Additionally, we looked for association between serum HDAC4 and DLCOsb (Single-breath diffusing capacity of the lung for carbon monoxide), as % of predicted by age, height, and gender, one of the main differences described between COPD-BS and COPD-TS. Women with COPD-BS were older and shorter and had a higher DLCOsb %P (percent predicted) compared to COPD-TS. Serum miR-22-3p was downregulated in COPD-BS relative to COPD-TS. In contrast, the concentration of HDAC4 was higher in COPD-BS compared to COPD-TS. Furthermore, a positive correlation between serum HDAC4 levels and DLCOsb %P was observed. We concluded that the miR-22-HDAC4-DLCO axis behaves differently in patients with COPD-BS and COPD-TS.

Indexed as

MicroRNAsAgedAged, 80 and overCohort StudiesCross-Sectional StudiesFemaleHistone DeacetylasesHumansMiddle AgedNicotianaPulmonary Disease, Chronic ObstructiveRepressor ProteinsSmokeSmokingTobacco Smoke PollutionHDAC4 protein, humanHistone DeacetylasesMicroRNAsMIRN22 microRNA, humanRepressor ProteinsSmokeTobacco Smoke Pollutionbiomass smokecopddlcohdac4mir-22tobacco smoking

Identifiers

PMID31817742
PMCPMC6995507
OpenAlexW2991950808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.